test

Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides

Conditions

Cutaneous Lymphoma | Cutaneous T-cell Lymphoma

What is the purpose of this trial?

The purpose of this study is to determine if vorinostat combined with low-dose total skin electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over low-dose TSEBT alone.



Participation Guidelines

Age:
18 Years and older
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Stanford University
Dates:
December 2010
Last Updated:
March 7, 2014
Study HIC#:
1008007299

Clinicaltrials.gov ID: NCT01187446